{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:37:39Z","timestamp":1790699859077,"version":"4.1.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["The CENTURION study was funded by Eli Lilly and Co"],"award-info":[{"award-number":["The CENTURION study was funded by Eli Lilly and Co"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A significant proportion of triptan users exhibit an insufficient response or inadequate tolerability to a triptan, and some may develop a contraindication. Lasmiditan, a selective 5-HT\n                      <jats:sub>1F<\/jats:sub>\n                      receptor agonist, may be an option for these individuals. We assessed lasmiditan efficacy in a subgroup of patients in CENTURION (Phase 3 migraine consistency study) who exhibited an insufficient response to triptans, including a subgroup with insufficient response due to efficacy only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized to lasmiditan 200\u2009mg for four attacks, lasmiditan 100\u2009mg for four attacks, or placebo for three and lasmiditan 50\u2009mg for one attack. Triptan insufficient responders were pre-defined as patients with insufficient efficacy or tolerability, or who developed a contraindication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In triptan insufficient responders, lasmiditan was superior to placebo ( p\u2009&lt;\u20090.05) for pain freedom beginning at 1\u2009h (both doses); pain relief beginning at 0.5 (200\u2009mg) or 1\u2009h (100\u2009mg); migraine-related disability freedom, much\/very much better on the Patient Global Impression of Change, and most bothersome symptom freedom at 2\u2009h; sustained pain freedom; and need for rescue medication. Lasmiditan showed benefit for consistency of effect across attacks for 2-h pain freedom and pain relief. Findings were similar in triptan responders and triptan na\u00efve patients and when the triptan insufficient response definition was based on efficacy only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lasmiditan was efficacious across multiple clinically relevant endpoints in the acute treatment of migraine independent of prior response to triptans. Trial Registration: CENTURION (NCT03670810); SAMURAI (NCT02439320); SPARTAN (NCT02605174)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024211048507","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:48:23Z","timestamp":1634158103000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-0725","authenticated-orcid":false,"given":"Uwe","family":"Reuter","sequence":"first","affiliation":[{"name":"Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Universit\u00e4tsmedizin Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Krege","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Lombard","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gomez Valderas","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Krikke-Workel","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Dell-Agnello","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherie A","family":"Dowsett","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C","family":"Buse","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"bibr1-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"bibr2-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098933"},{"key":"bibr3-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00404.x"},{"key":"bibr4-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05031.x"},{"key":"bibr5-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409354390"},{"key":"bibr6-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413512035"},{"key":"bibr7-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1111\/head.12404"},{"key":"bibr8-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"bibr9-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01110-9"},{"key":"bibr10-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"key":"bibr11-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1111\/head.13179"},{"key":"bibr12-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1111\/head.12962"},{"key":"bibr13-03331024211048507","unstructured":"GlaxoSmithKline. Imitrex (sumatriptan succinate) (package insert). Research Triangle Park, NC: GlaxoSmithKline, https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Imitrex_Tablets\/pdf\/IMITREX-TABLETS-PI-PIL.PDF (2017, accessed 14 July 2021)."},{"key":"bibr14-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"bibr15-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"bibr16-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419889350"},{"key":"bibr17-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989232"},{"key":"bibr18-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989247"},{"key":"bibr19-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419828967"},{"key":"bibr20-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.11.004"},{"key":"bibr21-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/2150132720963680"},{"key":"bibr22-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3495"},{"key":"bibr23-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410370873"},{"key":"bibr24-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001801"},{"key":"bibr25-03331024211048507","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.01.005"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211048507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024211048507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211048507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:17Z","timestamp":1777387757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024211048507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1177\/03331024211048507"],"URL":"https:\/\/doi.org\/10.1177\/03331024211048507","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}